Weight-loss drug may be launched in India next year, says Eli Lilly CEO David Ricks
US drug maker Eli Lilly plans to launch its weight-loss drugs Zepbound and Mounjaro in India next year. The company is considering pricing based on supply and volume expansion. Eli Lilly CEO David Ricks suggests focusing on digital services in the Indian healthcare industry to encourage innovation and improve access to healthcare. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 29, 2024 Category: Pharmaceuticals Source Type: news
The life-threatening dangers of the 'budget Ozempic' TikTokers are turning to because the weight-loss drug is too expensive
Ozempic is all the craze for weight loss in the US. But with its hefty price tag, many are turning to alternatives - such as 'budget Ozempic' laxatives. Doctors warn against this. (Source: the Mail online | Health)
Source: the Mail online | Health - February 28, 2024 Category: Consumer Health News Source Type: news
Why Is Vivani Medical (VANI) Stock Up 300% Today?
Little-known emerging biopharmaceutical company Vivani Medical (NASDAQ:VANI) saw its market value increase dramatically on Wednesday. Catapulting sentiment was the company’s weight-loss solution, which offered compelling results compared to mainline weight-loss therapeutics. Given Vivani’s…#vivanimedical #obese #ozempic #novonordisk #nvo #ozempicandwegovy #fda #wegovy #perjohnshopkins #maximgroups (Source: Reuters: Health)
Source: Reuters: Health - February 28, 2024 Category: Consumer Health News Source Type: news
US FDA Chief Very Concerned About Fake Weight Loss Drugs US FDA Chief Very Concerned About Fake Weight Loss Drugs
U.S. Food and Drug Administration Commissioner Dr. Robert Califf said on Wednesday that he is very concerned about the prevalence of compounded and fake versions of highly...Reuters Health Information (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - February 28, 2024 Category: Primary Care Tags: Diabetes & Endocrinology Source Type: news
Roswell Welcomes New Options Medical Weight Loss Clinic
Options Medical Weight Loss is excited to open its first clinic in the Metro Atlanta area. Options Medical Weight Loss is the nation's premier medical weight loss clinic offering non-surgical medical weight loss solutions that are safe, effective, and affordable. Board-certified obesity... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 28, 2024 Category: Pharmaceuticals Tags: CXP Source Type: news
Lilly could launch obesity drug in India next year, CEO says
Eli Lilly plans to launch its obesity drug, tirzepatide, in India next year. The drug, also known as Mounjaro for diabetes and Zepbound for weight-loss in the U.S., may see authorized generic versions. CEO David Ricks emphasized the need for India to enhance patent protection and eliminate redundant policies to attract global drugmaker investments. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 28, 2024 Category: Pharmaceuticals Source Type: news
Viking Therapeutics shares more than double on ‘statistically significant’ weight-loss trial results
US biotech group’s data suggests dominance of Novo Nordisk and Eli Lilly in the anti-obesity segment could be challenged in a few years (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 27, 2024 Category: Pharmaceuticals Source Type: news
Experimental weight-loss drug from a small biotech could outdo Ozempic
Viking Therapeutics posted results of an experimental drug that showed even better weight loss than the current market-leading drugs, a sign that the dominance of Ozempic and Mounjaro is far from assured. Get a curated selection of 10 of our best stories in your inbox every weekend. Viking said…#mounjaro #obese #elilillys #novonordisks #elililly #davidrisinger #leerinkpartners #novonordisk #novonordisksozempic #brianlian (Source: Reuters: Health)
Source: Reuters: Health - February 27, 2024 Category: Consumer Health News Source Type: news
Viking Therapeutics Catapults 73% As Weight-Loss Drug Beats Out Lilly's Zepbound
A weight-loss drug from Viking topped Lilly's Zepbound in a midstage study Tuesday. Viking stock nearly doubled, while Lilly shares slumped. The post Viking Therapeutics Catapults 73% As Weight-Loss Drug Beats Out Lilly's Zepbound appeared first on Investor's Business Daily.#lilly #zepbound (Source: Reuters: Health)
Source: Reuters: Health - February 27, 2024 Category: Consumer Health News Source Type: news
Here ’s What Americans Think of Weight Loss Drugs
Not every major medical innovation breaks through to the general public. But the buzzy weight loss drugs for people with obesity or Type 2 diabetes certainly have.
About 75% of Americans have heard of Ozempic, Wegovy and other brands of anti-obesity drugs, according to the results of a new Pew Research Center survey. (Wegovy and Zepbound are specifically approved to treat obesity, while Ozempic and Mounjaro are approved to treat people with Type 2 diabetes and can help them lose weight.)
[time-brightcove not-tgx=”true”]
The survey included more than 10,000 people of different ages, genders, races, ethni...
Source: TIME: Health - February 26, 2024 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Source Type: news
More Americans taking Ozempic will boost the US economy, Goldman says
More widespread use of powerful weight-loss drugs like Ozempic in the U.S. could boost the economy in the coming years, according to Goldman Sachs strategists. The bank estimates that weight-loss drugs, called GLP-1 agonists, could increase the nation's gross domestic product by an extra 1% over…#goldmansachs #glp1 #goldman #janhatzius #novonordisk #ozempicandwegovy #elililly #mounjaro #oprahwinfrey #tesla (Source: Reuters: Health)
Source: Reuters: Health - February 26, 2024 Category: Consumer Health News Source Type: news
Boehringer Ingelheim says weight-loss drug had positive impact on liver condition
German pharma group finds no unexpected side effects during trial, including at higher doses (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 26, 2024 Category: Pharmaceuticals Source Type: news
Zealand Shares Surge on Liver Drug Data From Boehringer Pact Zealand Shares Surge on Liver Drug Data From Boehringer Pact
Shares in Zealand Pharma soared 34% on Monday after an experimental weight-loss drug it is developing with Boehringer Ingelheim yielded what they called " groundbreaking " ...Reuters Health Information (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 26, 2024 Category: Drugs & Pharmacology Tags: Gastroenterology Source Type: news
Physiological perturbations in combat sports: weight cycling and metabolic function-a narrative review - Lebron MA, Stout JR, Fukuda DH.
Combat sports athletes seeking a competitive edge often engage in weight management practices to become larger than their opponents, which ultimately includes periods of gradual weight loss, rapid weight loss, and weight regain. This pattern of weight loss... (Source: SafetyLit)
Source: SafetyLit - February 26, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
How a protein shake could fight the side effects of Ozempic and Wegovy
Medical firm Abbott has launched a line of high-protein, low-fat milkshakes in the US that are designed to maintain muscle mass among people taking weight-loss drugs. (Source: the Mail online | Health)
Source: the Mail online | Health - February 25, 2024 Category: Consumer Health News Source Type: news
